Integra LifeSciences Holdings Corporation is a medical technology company operating in two segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment provides neurosurgical, neurocritical care, and otolaryngology (ENT) technologies, including the CUSA ultrasonic surgical aspirator platform, CereLink intracranial pressure monitors, DuraGen dural graft matrices, DuraSeal dural sealants, Mayfield cranial stabilization systems, Bactiseal antimicrobial catheters, and Certas programmable valves. It also offers specialty surgical instruments and ENT solutions such as the TruDi navigation system, RELIEVA SPINPLUS balloon sinuplasty system, and AERA Eustachian tube dilation system. The Tissue Technologies segment focuses on wound reconstruction, care, and private label manufacturing, utilizing regenerative platforms derived from bovine collagen, bovine dermis, porcine urinary bladder, human amniotic tissue, and resorbable synthetic mesh. Key products include Integra Skin, PriMatrix dermal repair scaffolds, MicroMatrix urinary bladder matrix, Cytal wound matrix, AmnioExcel placental allograft membranes, MediHoney wound dressings, SurgiMend collagen matrix, Gentrix surgical matrix, and DuraSorb monofilament mesh. Founded in 1989, the company serves healthcare professionals and patients globally, with significant presence in the U.S. market, addressing conditions such as brain tumors, hydrocephalus, burns, chronic wounds, and hernias.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage integralife.com
Sector Healthcare IR page investor.integralife.com
Tags
neurosurgery, wound care, regenerative medicine, surgical instruments, ent surgery, tissue engineering, hydrocephalus management, plastic surgery, biomaterials, private label, Codman Specialty Surgical, Tissue Technologies, CUSA, CUSA Clarity, CereLink, Codman Neurosurgical Accessories, DuraGen, DuraSeal, Mayfield, Bactiseal, Certas Plus, TruDi, RELIEVA SPINPLUS, AERA, MicroFrance, Integra Skin, PriMatrix, MicroMatrix, Cytal, AmnioExcel, AmnioExcel Plus, MediHoney, SurgiMend, Gentrix, DuraSorb, NeuraGen, Jarit, Acclarent, Integra DUO LED
Press page integralife.com/news

Metrics

Valuation  
Market cap $ 1.267B
Market cap (USD) $ 1.267B
P/E 101.75
PEG —
P/BV 1.19
P/S 0.76
P/OCF 9.02
P/FCF 14.77
Dividend yield —
Turnover / mcap —
Returns  
ROE -39.9%
ROI -27.2%
ROIC -19.5%
Profit margin -31.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 65.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score -52.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.635B 1.611B 1.542B 1.558B 1.542B 1.372B 1.518B 1.472B 1.188B 992.075M 882.734M 928.305M 836.214M 830.871M 780.078M 732.068M 682.487M 654.604M 550.459M 419.297M 277.935M 229.825M 185.599M 117.822M — —
Net profit -516.474M -6.944M 67.741M 180.55M 169.075M 133.892M 50.201M 60.801M 64.743M 74.564M -3.519M 34.004M -16.977M 41.204M 27.989M 65.669M 50.955M 34.933M 33.471M 29.407M 37.194M 17.197M 26.861M 35.277M 26.163M -11.425M
Free cash flow -31.052M 24.964M 73.09M 222.126M 264.405M 164.942M 161.896M 121.942M 71.041M 69.077M 61.07M 37.542M 5.417M -10.316M 65.903M 68.433M 117.997M 59.189M 24.454M 60.182M 48.795M 30.467M 30.983M 29.731M 12.841M -8.228M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 12.42 22.68 43.55 56.07 66.99 64.92 58.28 45.1 47.86 85.79 67.78 54.23 47.71 38.98 30.98 47.28 35.87 33.06 41.3 42.44 34.7 — — — — —
Price performance 12m -0.45 -0.48 -0.22 -0.16 0.03 0.11 0.29 -0.06 -0.44 0.27 0.25 0.14 0.22 0.26 -0.34 0.32 0.08 -0.2 -0.03 0.22 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 148M 252M 266M 275M 226M 232M 263M 259M 272M 279M
↳ YoY growth +12.1% +69.9% +5.5% +3.6% -18.1% +2.8% +13.6% -1.6% +5.0% +2.4%
↳ 5y CAGR +4.6% +17.0% +17.6% +15.9% +11.3% +9.4% +0.9% -0.5% -0.2% +4.3%
Lease liabilities (USD) — — — 110M 101M 105M 172M 182M 181M 177M
Cash and deposits (USD) 102M 175M 139M 199M 470M 513M 457M 276M 246M 235M
Intangible assets (USD) 561M 1.16B 1.08B 1.03B 989M 1.15B 1.13B 1.07B 1.21B 1.13B
Right-of-use assets (USD) — — — 94.5M 83.6M 84.5M 148M 156M 144M 141M
Cash flow detail
Operating cash flow (USD) 116M 115M 200M 231M 204M 312M 264M 140M 129M 50.4M
Purchases of property, plant and equipment (USD) -47.3M -43.5M -77.7M -69.5M -38.9M -48M -42.3M -66.9M -104M -81.4M
Purchases of intangible assets (USD) — — — — — — 0.00 0.00 -9.95M -14.2M
Change in receivables (cash effect) (USD) -17.5M -89.7M -17M -9.43M 52.1M 7.27M -33.9M 4.59M 7.4M -485,000
Change in inventories (cash effect) (USD) -9.58M 99,000 8.3M -43.3M -48.3M 5.37M -29.1M -59.8M -28.1M -46.8M
Change in payables (cash effect) (USD) -414,000 95.3M 3.59M 14.7M -57.5M 32.9M 17.3M -20.2M -2.67M 26.7M
Share buybacks (cash effect) (USD) — — 0.00 0.00 -100M 0.00 -125M -275M -52.5M -221,000
Interest paid (cash effect) (USD) -14.4M -32.3M -58.3M -48.9M -47.3M -43.2M -42.2M -44.3M -64.4M -81.4M
Income taxes paid (cash effect) (USD) -4.3M -14.6M -10.4M -16.2M -29.8M -49.5M -35.9M -23.6M -22.7M -17.2M
Share-based compensation (USD) 17.3M 21.6M 20.8M 21.3M 19.6M 36.2M 27.7M 20.1M 24.4M 18.6M
Operating cash flow before change in receivables (USD) 134M 204M 217M 241M 152M 305M 298M 135M 122M 50.9M
Free cash flow (OCF - PPE - intangibles) (USD) 69.1M 71M 122M 162M 165M 264M 222M 73.1M 15M -45.3M
Income detail
Research and development expense (USD) 58.2M 63.5M 78M 79.6M 77.4M 93.1M 101M 104M 115M 99M
↳ 5y CAGR +2.5% +4.5% +8.4% +9.1% +8.7% +9.9% +9.8% +6.0% +7.7% +5.0%
Total comprehensive income (USD) 65.3M 98.1M 39.2M 19.2M 136M 198M 236M 42.4M -19.4M -519M
Comprehensive income to owners (USD) 65.3M 98.1M 39.2M 19.2M 136M 198M 236M 42.4M -19.4M -519M
Provision for credit losses (USD) 400,000 2M 600,000 2.1M 3.6M -1.1M 200,000 3M 3.4M 3.2M
Credit cost ratio (credit losses / average receivables) (%) 0.3% 1.0% 0.2% 0.8% 1.4% 0.5% 0.1% 1.1% 1.3% 1.2%
Reported Mar 1, 2018 Mar 1, 2018 Feb 23, 2021 Feb 23, 2021 Feb 23, 2021 Feb 24, 2022 Feb 25, 2025 Feb 25, 2025 Feb 25, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

<< Back

Press Release

Nov 6, 2026

Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference

PDF Version

PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 2:45 p.m. ET.

A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.

Investor Relations

Chris Ward Senior Director, Investor Relations (609) 772-7736 [email protected]

Media

Laurene Isip Vice President, Corporate Communications (609) 208-8121 [email protected]

Close

October 30, 2026

CNS 2026 October 30, 2026

Integra LifeSciences participates in the 2026 Congress of Neurological Surgeons (CNS) Annual Meeting.

At this year's meeting, Integra will showcase its comprehensive neurosurgery portfolio through interactive educational experiences, hands-on training and technologies that support neurosurgeons across the continuum of care.

Conference attendees are invited to visit Integra at Booth 341 and participate in the CNS Skills Showdown, an interactive, educational experience that allows surgeons to test and refine procedural skills while learning about innovative neurosurgical technologies.

In addition, Integra will host a mobile hands-on laboratory on-site on Tuesday, November 3, providing attendees with practical product training opportunities across key areas of neurosurgical care, including:

  • Aurora® Surgiscope® System
  • DuraGen®Dural Graft Matrices, Durepair® Dura Regeneration Matrix and dural repair solutions
  • CUSA® Clarity Ultrasonic Surgical Aspirator System
  • Neurocritical care technologies and intracranial pressure (ICP) monitoring solutions

"As a practicing neurosurgeon, I've seen how hands-on experience and peer collaboration help turn innovation into meaningful advances in patient care,” said Ray Turner, M.D., corporate vice president and chief medical officer, Integra LifeSciences. “Some of the most important conversations in our field happen when surgeons share what they’re seeing in practice, challenge conventional thinking and learn from each other's experiences. Integra technologies have long been part of my go-to toolkit, and I’m proud to stand behind products I also rely on in my own practice.”

An estimated 13.8 million patients worldwide require neurosurgical intervention each year, underscoring the importance of continued innovation, education, and collaboration across the specialty.1 Integra's neurosurgery portfolio includes technologies spanning neurocritical care, cerebrospinal fluid management, dural repair, visualization and tissue resection. The portfolio brings together established technologies such as the CUSA Clarity, celebrating 20 years within Integra's neurosurgery portfolio, alongside newer innovations such as Aurora® Surgiscope® System.

1 Dewan MC, Rattani A, Fieggen G, et al. Global neurosurgery: the current capacity and deficit in the provision of essential neurosurgical care. Executive Summary of the Global Neurosurgery Initiative at the Program in Global Surgery and Social Change. Journal of Neurosurgery. 2018;130(4):1055-1064. doi:10.3171/2017.11.JNS171500.

Read the press release here .

Get in touch

Quick links

Integra logo

Privacy Policy Terms of Use

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Terms of Use and our Privacy Policy . Use of this site and the information on this site is subject to our Terms of Use and constitutes your consent to our Privacy Policy and to the application of such U.S. laws and regulations. Contact us with any questions or for more information.

© Copyright 2017-2026 Integra LifeSciences Corporation. All rights reserved.

A career built on purpose and growth Bull 0 Bear 0 Routine

October 26, 2026

Omar Santiago Thumbnail October 26, 2026

Over 25 years with Integra LifeSciences, Omar has taken on new challenges, including a transition into environmental health and safety, where he discovered a new sense of purpose.

Your tenure with Integra LifeSciences dates back to 2001. Congratulations on reaching 25 years! Tell us about how your journey began.

Omar: When I began on this path in 2001, I was just looking for a job. Back then, I didn't know much about the medical technology industry or where it would lead. As I learned more about the products and their impact, I began to appreciate that the work we were doing could help restore lives. Over time, Integra gave me opportunities, purpose, and a career path that I never expected.

What has kept you motivated throughout your career?

Omar: In 2018, I had the opportunity to move into the environmental, health and safety area, and that gave me a whole new sense of purpose. In this role, no two days are ever the same. What keeps me engaged is working with people across the organization and learning something new every day. I've also been fortunate to have incredible leaders and mentors who believed in me and supported my growth.

How would you describe your leadership style?

Omar: I believe you can't lead from behind a monitor. If you're asking people to do something, you should be willing to do it yourself. I like being on the floor, talking with colleagues, celebrating small wins, and understanding their challenges. A simple "thank you" or "great job" goes a long way. Building relationships and earning trust are essential, especially in safety, where you're often asking people to embrace change.

Through business resource groups, Integra encourages colleagues to bring their whole selves to work. One of our business resource groups, UNIDOS, celebrates Latin and Hispanic culture through events and networking opportunities for members. How has your Hispanic heritage influenced your work?

Omar: Being bilingual has helped me connect with colleagues from different backgrounds, especially Spanish-speaking team members. Whether visiting our site in Añasco, Puerto Rico or supporting colleagues at our Mansfield site, being able to communicate in the language a colleague is most comfortable using can make safety and compliance requirements clearer and more accessible. It supports trust, helps reduce misunderstandings, and ensures colleagues have the information they need to work safely.

How has being your true self enabled the relationship building that allowed for growth?

Omar: My mentors valued my opinions and encouraged open communication. I've learned that leadership is about creating a platform where people feel comfortable sharing ideas and concerns. That openness creates accountability and drives better outcomes.

Looking back, what does Integra mean to you?

Omar: Integra gave me a roadmap when I didn't have one. It provided opportunities, purpose, and a place where I genuinely enjoy coming to work. I'm grateful for both the big and small things the company has given me, and for the chance to help ensure people go home safely every day. That's what makes the work worthwhile.

7713373

Get in touch

Quick links

Integra logo

Privacy Policy Terms of Use

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Terms of Use and our Privacy Policy . Use of this site and the information on this site is subject to our Terms of Use and constitutes your consent to our Privacy Policy and to the application of such U.S. laws and regulations. Contact us with any questions or for more information.

© Copyright 2017-2026 Integra LifeSciences Corporation. All rights reserved.

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Privacy Policy

Cookies Settings Reject All Non-Necessary Accept All Cookies

Company Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Back Button

Cookie List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All Non-Necessary Confirm My Choices

Powered by Onetrust

Prompts

Integra LifeSciences Holdings Corporation (ticker IART), listed in United States.

ETFs Holding Integra LifeSciences Holdings Corporation

ETF Weight in ETF Shares Market value As of
SQLV 0.26% 4,079 $ 73.259K Jun 30, 2026
ESSC 0.19% 4,086 $ 68.032K Jul 31, 2026
VFVA 0.14% 76,361 $ 1.292M Aug 31, 2026
MSSM 0.12% 49,548 $ 838.352K Aug 31, 2026
VFMF 0.11% 65,660 $ 1.111M Aug 31, 2026
BSVO 0.09% 162,103 $ 2.2M Nov 18, 2026
AVSC 0.06% 141,031 $ 1.972M Nov 16, 2026
DFSV 0.06% 1,126,542 $ 16.166M Nov 12, 2026
RESM 0.06% 114 $ 2,047.44 Jun 30, 2026
JMEE 0.02% 45,824 $ 620.915K Nov 17, 2026
DFAT 0.02% 401,671 $ 5.764M Nov 12, 2026
DFAS 0.01% 330,624 $ 4.744M Nov 12, 2026
DXUV 0.01% 26,432 $ 379.299K Nov 12, 2026
DCOR 0.00% 116,500 $ 1.672M Nov 12, 2026
DFAC 0.00% 192,679 $ 2.765M Nov 12, 2026
DFAU 0.00% 19,275 $ 276.596K Nov 12, 2026
DFSU 0.00% 3,400 $ 48.79K Nov 12, 2026
DFUS 0.00% 19,172 $ 275.118K Nov 12, 2026
DFUV 0.00% 1,313 $ 18.842K Nov 12, 2026
EBI 0.00% 34 $ 575.28 Aug 31, 2026
AVUS 0.00% 21,705 $ 303.436K Nov 16, 2026
AVSU 0.00% 383 $ 5,354.34 Nov 16, 2026